Insights

Focused Rare Disease Pipeline Retrophin’s strong emphasis on developing therapies for rare kidney and liver diseases such as FSGS, IgAN, and NGLY1 deficiency positions it as a key provider for healthcare organizations specializing in nephrology and hepatology. Building partnerships or providing complementary products in these niches could create lucrative sales opportunities.

Established Commercial Presence With four approved products generating revenue and a pipeline of late-stage development programs, Retrophin demonstrates a solid commercial and R&D foundation. This stability offers multiple touchpoints for introducing innovative solutions, services, or complementary therapeutics to enhance their offerings and support their growth objectives.

Partnership and Acquisition Potential Retrophin’s history of collaborations—such as with Asklepionpharm and Censa Pharmaceuticals—suggests openness to strategic partnerships and acquisitions. Engaging with them through licensing, joint ventures, or supply agreements can unlock new sales channels and expand their treatment portfolio.

Patient-Centric Approach Retrophin’s mission-driven culture centered on patient outcomes and community engagement indicates opportunities to provide patient support solutions, adherence technologies, or educational programs that align with their focus on improving treatment access and clinical outcomes.

Emerging Market Visibility As Retrophin transitions into a fully integrated biopharmaceutical company with recent fundraisings and pipeline advancements, there is potential to engage in joint marketing programs or supply agreements that capitalize on their growth trajectory in rare disease therapeutics.

Retrophin Tech Stack

Retrophin uses 8 technology products and services including Linkedin Insight Tag, jsDelivr, OneTrust, and more. Explore Retrophin's tech stack below.

  • Linkedin Insight Tag
    Analytics
  • jsDelivr
    Content Delivery Network
  • OneTrust
    Cookie Compliance
  • DreamWeaver
    Editors
  • Google Fonts API
    Font Scripts
  • Cloudflare Bot Management
    Security
  • X-Content-Type-Options
    Web & Portal Technology
  • Drupal Multisite
    Web Hosting

Media & News

Retrophin's Email Address Formats

Retrophin uses at least 1 format(s):
Retrophin Email FormatsExamplePercentage
First.Last@retrophin.comJohn.Doe@retrophin.com
92%
LFirst@retrophin.comDJohn@retrophin.com
3%
First.Middle@retrophin.comJohn.Michael@retrophin.com
3%
First@retrophin.comJohn@retrophin.com
2%

Frequently Asked Questions

Where is Retrophin's headquarters located?

Minus sign iconPlus sign icon
Retrophin's main headquarters is located at 3721 Valley Centre Drive Suite 200 San Diego, CA 92130 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Retrophin's phone number?

Minus sign iconPlus sign icon
You can contact Retrophin's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Retrophin's stock symbol?

Minus sign iconPlus sign icon
Retrophin is a publicly traded company; the company's stock symbol is TVTX.

What is Retrophin's official website and social media links?

Minus sign iconPlus sign icon
Retrophin's official website is retrophin.com and has social profiles on LinkedIn.

How much revenue does Retrophin generate?

Minus sign iconPlus sign icon
As of July 2025, Retrophin's annual revenue is estimated to be $862K.

What is Retrophin's SIC code NAICS code?

Minus sign iconPlus sign icon
Retrophin's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Retrophin have currently?

Minus sign iconPlus sign icon
As of July 2025, Retrophin has approximately 72 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: F. K.Chief Medical Officer: N. R.Vice President Regulatory Affairs: J. W.. Explore Retrophin's employee directory with LeadIQ.

What industry does Retrophin belong to?

Minus sign iconPlus sign icon
Retrophin operates in the Biotechnology Research industry.

What technology does Retrophin use?

Minus sign iconPlus sign icon
Retrophin's tech stack includes Linkedin Insight TagjsDelivrOneTrustDreamWeaverGoogle Fonts APICloudflare Bot ManagementX-Content-Type-OptionsDrupal Multisite.

What is Retrophin's email format?

Minus sign iconPlus sign icon
Retrophin's email format typically follows the pattern of First.Last@retrophin.com. Find more Retrophin email formats with LeadIQ.

When was Retrophin founded?

Minus sign iconPlus sign icon
Retrophin was founded in 2011.
Retrophin

Retrophin

Biotechnology ResearchCalifornia, United States51-200 Employees

At Retrophin, our number one priority will always be the patients we serve – they are “why” we come to work each day.  Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision – to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease=community that is dedicated to giving patients a chance and providing hope. 

Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets. 

Through our portfolio of approved products and promising pipeline focused on hepatology and nephrology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.

Please read our community guidelines to understand how we manage our social media engagement: retrophin.com/community-guidelines

Section iconCompany Overview

Headquarters
3721 Valley Centre Drive Suite 200 San Diego, CA 92130 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
TVTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
51-200

Section iconFunding & Financials

  • $10M$25M

    Retrophin's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    Retrophin's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.